Key Points of The Revised Guidelines:
- Background and Objective:
- The pharmaceutical industry is crucial for both wellness and employment in India.
- The scheme supports the enhancement of manufacturing capabilities through Production Linked Incentive (PLI) schemes.
- The guidelines address the need for support to existing pharma clusters and MSMEs to improve productivity, quality, and sustainability.
- Existing Schemes:
- The document consolidates three existing sub-schemes into a single scheme:
- Assistance to Pharmaceutical Industry for Common Facilities (APICF).
- Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS).
- Pharmaceutical Promotion and Development Scheme (PPDS).
- The document consolidates three existing sub-schemes into a single scheme:
- Definitions:
- Key terms such as “Beneficiary,” “Capital subsidy,” “Cluster development,” “Common facilities,” and others are defined to provide clarity on the scheme’s provisions.
- Objective of the Scheme:
- Strengthening infrastructure to make India a global leader in the pharmaceutical sector.
- Upgrading production facilities to meet regulatory standards.
- Promoting knowledge and awareness in the pharmaceutical and medical devices industry.
Components And Incentives of the Scheme
APICF: Strengthening pharmaceutical clusters by creating common facilities.
Incentive under the scheme The limit of incentive will be 70% of the approved project cost or Rs 20 cr., whichever is less, as per approval of SSC. In the case of Himalayan States and States in the North East Region, the grant-in-aid would be Rs. 20 Crore per Cluster or 90% of the project cost of the Common Infrastructure Facilities (CIF),
RPTUAS: Assisting existing pharma units to meet national and international standards.Incentive under the scheme Pharmaceutical units with following average turnover criterion for the last three years will be eligible for incentive subject to a maximum of Rs. 1.00 crore as under:- Turnover from Rs. 1.00 crore to less than Rs. 50.00 crore:- 20% of investment under eligible activities; Turnover from Rs. 50.00 crore to less than Rs. 250.00 crore:- 15% of investment under eligible activities; Turnover from Rs. 250.00 crore to less than Rs. 500.00 crore:- 10% of investment under eligible activities;
PPDS: Promoting the development of the pharmaceutical and medical devices sector through studies, seminars, and conferences.
